Autres langues Adhera Therapeutics, Inc.

Actions

ATRX

US00687E4061

Marché Fermé - OTC Markets Autres places de cotation 17:58:11 14/05/2024			Varia. 5j.	Varia. 1 janv.
0,0081 ^USD	+55,77%		+55,77%	-73,00%

18/01	Adhera Therapeutics, Inc. reçoit une notification écrite de Melior Pharmaceuticals II, LLC de son choix de résilier l'accord de licence	CI
16/01	Adhera Therapeutics, Inc. annonce la démission de Zahed Subhan en tant que directeur général	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Adhera Therapeutics, Inc. Receives Written Notice from Melior Pharmaceuticals II, LLC of Election to Terminate the License Agreement	18/01
Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive Officer	16/01
Adhera Therapeutics, Inc. Announces Board Resignations	16/01
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	20/11
BigTime Penny Stocks: OTCQB Venture Market Watchlist (WOEN, ATRX, EDXC, CBDS, OMTK)	17/10/23
Adhera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/08/23
Thinking about buying stock in Vistagen Therapeutics, Origin Materials, MedAvail Holdings, United States Lime & Minerals, or Adhera Therapeutics?	10/08/23
Adhera Therapeutics, Inc. announced that it has received $0.105 million in funding	22/06/23
Adhera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	22/05/23
Adhera Therapeutics, Inc. announced that it has received $0.1 million in funding	28/04/23
Adhera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23
Adhera Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	31/03/23
Adhera Therapeutics, Inc. announced that it has received $0.214285 million in funding	02/03/23
Adhera Therapeutics, Inc. announced that it has received $0.364285 million in funding	16/02/23
Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes	25/01/23
Adhera Therapeutics, Inc. announced that it has received $0.1 million in funding	15/12/22
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22
Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist	19/09/22
Adhera Therapeutics, Inc. Elects Zahed Subhan as Chairman of the Board	19/09/22
ADHERA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure (form 8-K)	09/09/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Adhera Therapeutics, Inc.

Actions

ATRX

US00687E4061

Autres langues

Filtres